company background image
AVDL logo

Avadel Pharmaceuticals NasdaqGM:AVDL Stock Report

Last Price

US$15.82

Market Cap

US$1.5b

7D

-1.7%

1Y

n/a

Updated

22 May, 2024

Data

Company Financials +

Avadel Pharmaceuticals plc

NasdaqGM:AVDL Stock Report

Market Cap: US$1.5b

Avadel Pharmaceuticals plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Avadel Pharmaceuticals
Historical stock prices
Current Share PriceUS$15.82
52 Week HighUS$19.09
52 Week LowUS$14.77
Beta0
1 Month Change-8.55%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-6.94%

Recent News & Updates

Recent updates

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Apr 02

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Mar 05

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Jan 28

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Jan 16
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Jan 11

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

Sep 22
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Aug 01
Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

May 03
Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Aug 31

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Jul 07
Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Jun 29

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Jun 16

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Mar 21

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Mar 15
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Nov 19
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals: I Am Holding

Nov 01

Avadel Pharmaceuticals, The Jazz-Killer

Aug 05

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jul 23
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Jun 09

Avadel Pharmaceuticals EPS beats by $0.09

May 10

Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Mar 11
Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?

Feb 05
Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?

Avadel Pharmaceuticals' (NASDAQ:AVDL) Stock Price Has Reduced 35% In The Past Three Years

Jan 10
Avadel Pharmaceuticals' (NASDAQ:AVDL) Stock Price Has Reduced 35% In The Past Three Years

Avadel files US application for its lead drug

Dec 16

Avadel's Xyrem Competitor: A Quick Overview

Dec 15

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Dec 15
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Shareholder Returns

AVDLUS PharmaceuticalsUS Market
7D-1.7%0.5%-0.2%
1Yn/a17.9%28.2%

Return vs Industry: Insufficient data to determine how AVDL performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AVDL performed against the US Market.

Price Volatility

Is AVDL's price volatile compared to industry and market?
AVDL volatility
AVDL Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement5.9%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market2.8%

Stable Share Price: AVDL has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine AVDL's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015154Greg Diviswww.avadel.com

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Avadel Pharmaceuticals plc Fundamentals Summary

How do Avadel Pharmaceuticals's earnings and revenue compare to its market cap?
AVDL fundamental statistics
Market capUS$1.54b
Earnings (TTM)-US$156.83m
Revenue (TTM)US$55.14m

27.6x

P/S Ratio

-9.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVDL income statement (TTM)
RevenueUS$55.14m
Cost of RevenueUS$2.37m
Gross ProfitUS$52.77m
Other ExpensesUS$209.61m
Earnings-US$156.83m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.63
Gross Margin95.71%
Net Profit Margin-284.42%
Debt/Equity Ratio43.8%

How did AVDL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.